Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial

Reuters2026/07/23 20:00

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genmab issued a clarification correcting how primary endpoints were described for the Phase 3 EPCORE DLBCL-1 epcoritamab trial.
In the U.S., overall survival was the sole primary endpoint; the study missed it, with no statistically significant overall survival improvement.
The trial uses region-specific primary endpoints, creating a mismatch with earlier topline messaging; additional results are slated for journal submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723712759) on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial

You may also like

Crypto prices